Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The hypothesis for this study is that there is a dose-response relationship in patients treated with 177Lu-DOTATATE for meningiomas.
Dosimetry is essential for Peptide Receptor Radionuclide Therapy (PRRT) of meningiomas, to predict efficacy and dose-effect relationships at the individual level, and to move towards personalized medicine. Due to the increasing therapeutic applications of Lutathera, the European Association of Nuclear Medicine (EANM) recently issued recommendations on the dosimetry of 177Lu-labeled somatostatin analogues. Nevertheless, despite these recommendations, the evaluation of meningioma tumor dosimetry in Peptide Receptor Radionuclide Therapy studies is not systematic, which has not enabled us to clearly determine the dose delivered to the meningioma lesion in these treatments and the possible dose-response relationship in this type of treatment.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Patients treated with 177Lu-DOTATATE for meningioma | Patients treated with 177Lu-DOTATATE for meningioma at the Nancy's hospital who met the treatment criteria of the Compassionate Prescribing Framework and received a scintigraphy at D1, D4 and D7 (± 1 day) |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| tumoral dosimetry by scintigraphy | Diagnostic Test | The tumoral dosimetry has been done on patient after treatment by 177Lu-DOTATATE Theses patients performed a scintigraphy exam at D1, D4 and D7 after the treatment |
| Measure | Description | Time Frame |
|---|---|---|
| Diagnostic accuracy for progression free survival | Accuracy of tumor dosimetry to predict 6-month progression-free survival. | Day 1 |
| Measure | Description | Time Frame |
|---|---|---|
| Diagnostic accuracy for overal survival | Accuracy of tumoral dosimetry in predicting 6-month overall survival | Day 1 |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
patients treated with 177Lu-DOTATATE for meningioma at Nancy University Hospital
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| CHRU de NANCY | Vandœuvre-lès-Nancy | 54511 | France | |||
| Nuclear medicine Department CHRU de NANCY |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 40982021 | Result | Boursier C, Zaragori T, Garabedian N, Blonski M, Obara T, Taillandier L, Imbert L, Verger A. [177Lu]Lu-DOTATATE for refractory meningiomas: factors associated with the therapeutic response and initial tumor dosimetric data. Eur J Nucl Med Mol Imaging. 2026 Feb;53(3):2047-2053. doi: 10.1007/s00259-025-07555-x. Epub 2025 Sep 22. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D008579 | Meningioma |
| ID | Term |
|---|---|
| D009380 | Neoplasms, Nerve Tissue |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
| D009383 | Neoplasms, Vascular Tissue |
Not provided
Not provided
Not provided
Not provided
Not provided
| Vandœuvre-lès-Nancy |
| 54511 |
| France |
| D008577 | Meningeal Neoplasms |
| D016543 | Central Nervous System Neoplasms |
| D009423 | Nervous System Neoplasms |
| D009371 | Neoplasms by Site |
| D009422 | Nervous System Diseases |